Published in Cancer Res on December 15, 2007
mTOR signaling in growth control and disease. Cell (2012) 29.21
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell (2009) 3.78
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
mTOR complex 2 signaling and functions. Cell Cycle (2011) 2.66
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene (2010) 2.22
A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. J Biol Chem (2010) 1.75
mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol (2010) 1.65
Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res (2009) 1.61
Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res (2009) 1.58
The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol (2010) 1.49
Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal (2009) 1.47
A drosophila model for EGFR-Ras and PI3K-dependent human glioma. PLoS Genet (2009) 1.43
Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. Genes Dev (2010) 1.43
Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci (2011) 1.37
mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol (2012) 1.24
Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev (2010) 1.21
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer (2010) 1.21
Review series: TOR kinase complexes and cell migration. J Cell Biol (2011) 1.19
TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells. BMC Cancer (2008) 1.18
Akt and mTOR in B Cell Activation and Differentiation. Front Immunol (2012) 1.16
Deconvoluting mTOR biology. Cell Cycle (2012) 1.16
mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J (2011) 1.14
Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol (2012) 1.13
Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle. Hum Mol Genet (2009) 1.11
Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol (2012) 1.08
Rictor regulates cell migration by suppressing RhoGDI2. Oncogene (2012) 1.06
In vivo analysis of protein kinase B (PKB)/Akt regulation in DNA-PKcs-null mice reveals a role for PKB/Akt in DNA damage response and tumorigenesis. J Biol Chem (2008) 1.04
Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochem Biophys Res Commun (2008) 1.03
Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer. Clin Cancer Res (2008) 1.02
MiR-424/503-mediated Rictor upregulation promotes tumor progression. PLoS One (2013) 1.02
Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways. FEBS Open Bio (2014) 1.01
Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma. Mol Cancer Ther (2011) 0.99
mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood (2011) 0.99
Mammalian TOR signaling to the AGC kinases. Crit Rev Biochem Mol Biol (2011) 0.97
Alcohol-induced modulation of rictor and mTORC2 activity in C2C12 myoblasts. Alcohol Clin Exp Res (2011) 0.95
TORC2-a new player in genome stability. EMBO Mol Med (2014) 0.94
TOR complex 2-Ypk1 signaling maintains sphingolipid homeostasis by sensing and regulating ROS accumulation. Cell Rep (2014) 0.94
Conditional astroglial Rictor overexpression induces malignant glioma in mice. PLoS One (2012) 0.93
The mTOR signalling cascade: paving new roads to cure neurological disease. Nat Rev Neurol (2016) 0.93
Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion. PLoS One (2013) 0.92
mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions. Mol Biol Int (2014) 0.92
Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol Med (2014) 0.88
The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer. Oncotarget (2015) 0.88
microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion. Exp Cell Res (2014) 0.87
Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study. BMC Cancer (2013) 0.86
The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells. PLoS One (2013) 0.86
PI3K regulation of the SKP-2/p27 axis through mTORC2. Oncogene (2012) 0.86
mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene (2016) 0.85
Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells. PLoS One (2013) 0.85
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat (2013) 0.84
Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics. Int J Mol Sci (2013) 0.84
The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype. J Neuroinflammation (2014) 0.84
Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model. PLoS One (2013) 0.84
Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine. Oncotarget (2015) 0.84
The mTOR signaling pathway as a treatment target for intracranial neoplasms. Neuro Oncol (2014) 0.84
Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness. J Biol Chem (2015) 0.82
Transforming Growth Factor-β Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion. Am J Pathol (2016) 0.82
Protor-2 interacts with tristetraprolin to regulate mRNA stability during stress. Cell Signal (2011) 0.82
Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats. Neuro Oncol (2011) 0.81
Tetraspanin 8-rictor-integrin α3 complex is required for glioma cell migration. Int J Mol Sci (2015) 0.81
Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. Mol Cancer Ther (2015) 0.81
Conditional disruption of rictor demonstrates a direct requirement for mTORC2 in skin tumor development and continued growth of established tumors. Carcinogenesis (2015) 0.80
Niacin protects against UVB radiation-induced apoptosis in cultured human skin keratinocytes. Int J Mol Med (2012) 0.80
Mechanisms mediating the effects of alcohol and HIV anti-retroviral agents on mTORC1, mTORC2 and protein synthesis in myocytes. World J Biol Chem (2012) 0.80
TOR complex 2-Ypk1 signaling is an essential positive regulator of the general amino acid control response and autophagy. Proc Natl Acad Sci U S A (2014) 0.80
Drosophila melanogaster as a model system for human brain cancers. Glia (2011) 0.80
AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest. PLoS One (2016) 0.80
mTORC2 modulates feedback regulation of p38 MAPK activity via DUSP10/MKP5 to confer differential responses to PP242 in glioblastoma. Genes Cancer (2014) 0.79
Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Front Pharmacol (2016) 0.77
microRNA-153 Targets mTORC2 Component Rictor to Inhibit Glioma Cells. PLoS One (2016) 0.77
Rapamycin induces the anti-apoptotic protein survivin in neuroblastoma. Int J Biochem Mol Biol (2012) 0.76
Rictor negatively regulates high-affinity receptors for IgE-induced mast cell degranulation. J Immunol (2014) 0.76
Significance of filamin A in mTORC2 function in glioblastoma. Mol Cancer (2015) 0.76
Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma. J Biol Chem (2016) 0.75
Human Dynactin-Associated Protein Transforms NIH3T3 Cells to Generate Highly Vascularized Tumors with Weak Cell-Cell Interaction. PLoS One (2015) 0.75
Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme. Oncotarget (2016) 0.75
Evaluation of Akt and RICTOR Expression Levels in Astrocytomas of All Grades. J Histochem Cytochem (2016) 0.75
Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide. Oncoscience (2016) 0.75
The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity. Neuro Oncol (2017) 0.75
Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer. Am J Transl Res (2017) 0.75
mTORC2 regulates hedgehog pathway activity by promoting stability to Gli2 protein and its nuclear translocation. Cell Death Dis (2017) 0.75
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther (2005) 3.27
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res (2002) 1.93
Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem (2005) 1.89
In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood (2004) 1.43
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood (2010) 1.35
Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem (2002) 1.27
Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling. J Biol Chem (2008) 1.22
Downstream effectors of oncogenic ras in multiple myeloma cells. Blood (2002) 1.20
Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone (2006) 1.18
Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res (2006) 1.14
Targeting cancer with a lupus autoantibody. Sci Transl Med (2012) 1.09
Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochem Biophys Res Commun (2008) 1.03
Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma. Mol Cancer Ther (2011) 0.99
IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1. J Biol Chem (2010) 0.98
Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. Mol Cancer Ther (2009) 0.98
Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. Oncogene (2004) 0.97
Conditional astroglial Rictor overexpression induces malignant glioma in mice. PLoS One (2012) 0.93
AP-1 regulates cyclin D1 and c-MYC transcription in an AKT-dependent manner in response to mTOR inhibition: role of AIP4/Itch-mediated JUNB degradation. Mol Cancer Res (2010) 0.92
Effects of PHEX antisense in human osteoblast cells. J Am Soc Nephrol (2002) 0.91
Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis. J Oncol (2013) 0.90
Stepwise renal lineage differentiation of mouse embryonic stem cells tracing in vivo development. Biochem Biophys Res Commun (2011) 0.88
Increased cathepsin D release by Hyp mouse osteoblast cells. Am J Physiol Endocrinol Metab (2005) 0.84
Altered cathepsin D metabolism in PHEX antisense human osteoblast cells. Biochem Biophys Res Commun (2005) 0.82
Protein kinase C regulates internal initiation of translation of the GATA-4 mRNA following vasopressin-induced hypertrophy of cardiac myocytes. J Biol Chem (2007) 0.82
Protor-2 interacts with tristetraprolin to regulate mRNA stability during stress. Cell Signal (2011) 0.82
Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells. Mol Cancer Ther (2003) 0.77
Effective induction of cells expressing GABAergic neuronal markers from mouse embryonic stem cell. In Vitro Cell Dev Biol Anim (2013) 0.76
Hypertonicity increases CLC-5 expression in mouse medullary thick ascending limb cells. Am J Physiol Renal Physiol (2004) 0.76